BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37571885)

  • 1. Expression and clinical significance of PD-1 in UCEC and its Impact on tumor.
    Xing F; Yang Y; Zheng W
    Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):168-173. PubMed ID: 37571885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data.
    Pan Y; Jia LP; Liu Y; Han Y; Deng Q
    J Ovarian Res; 2019 Aug; 12(1):81. PubMed ID: 31472672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
    Zheng J; Zhang YW; Pan ZF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
    Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
    J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
    Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
    Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
    Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
    Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
    Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
    Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Hub Genes Correlated With Poor Prognosis for Patients With Uterine Corpus Endometrial Carcinoma by Integrated Bioinformatics Analysis and Experimental Validation.
    Yuan Y; Chen Z; Cai X; He S; Li D; Zhao W
    Front Oncol; 2021; 11():766947. PubMed ID: 34868993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
    Wang Z; Xing L; Huang Y; Han P
    Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel key genes associated with uterine corpus endometrial carcinoma progression and prognosis.
    Li H; Zhou Q; Wu Z; Lu X
    Ann Transl Med; 2023 Jan; 11(2):100. PubMed ID: 36819577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer.
    Lei P; Wang H; Yu L; Xu C; Sun H; Lyu Y; Li L; Zhang DL
    Int Immunopharmacol; 2022 Jul; 108():108743. PubMed ID: 35413679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Analysis of ESRRA in Endometrial Cancer.
    Wang S; Huo X
    Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer.
    Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z
    Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and validation of potential markers associated with uterine corpus endometrial carcinoma and polycystic ovary syndrome based on bioinformatics methods.
    Wu R; Wu C; Zhu B; Li J; Zhao W
    Front Mol Biosci; 2023; 10():1192313. PubMed ID: 37363398
    [No Abstract]   [Full Text] [Related]  

  • 17. Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma.
    Li D; Zhang J; Wu L; Yang X; Chen Z; Yuan J
    Cancer Manag Res; 2021; 13():7311-7323. PubMed ID: 34584457
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
    Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma.
    Xue S; Su XM; Ke LN; Huang YG
    Front Oncol; 2023; 13():1077780. PubMed ID: 36845675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
    Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z
    World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.